--- title: "FibroBiologics Launches New At-The-Market Equity Offering" type: "News" locale: "en" url: "https://longbridge.com/en/news/284941425.md" description: "FibroBiologics, Inc. has launched an at-the-market equity offering agreement with H.C. Wainwright & Co. to issue up to $6.15 million in common stock. The company will pay a 3.0% commission on gross proceeds and plans to use the net proceeds for working capital. The offering is part of FibroBiologics' strategy to maintain flexible access to equity capital, though it may signal potential dilution for existing shareholders. The current analyst rating for FBLG stock is a Buy with a price target of $8.00, but concerns about financial performance and technical setup persist." datetime: "2026-05-01T21:08:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284941425.md) - [en](https://longbridge.com/en/news/284941425.md) - [zh-HK](https://longbridge.com/zh-HK/news/284941425.md) --- # FibroBiologics Launches New At-The-Market Equity Offering ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from FibroBiologics, Inc. ( (FBLG) ). On May 1, 2026, FibroBiologics, Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co. that allows the company to issue and sell up to $6.15 million of its common stock from time to time through the sales agent. Under the arrangement, FibroBiologics will pay a 3.0% commission on gross proceeds plus specified legal and due diligence reimbursements, may also sell shares to the agent as principal, and expects to use any net proceeds for working capital and general corporate purposes, with no obligation to sell any shares and the offering terminating once the cap is reached or the agreement is ended. Shares sold under the agreement, if any, will be issued pursuant to FibroBiologics’ shelf registration statement on Form S-3 that was filed on February 3, 2025 and declared effective on February 10, 2025, supported by a base prospectus and a dedicated ATM prospectus supplement. The deal includes customary indemnification and contribution provisions for the sales agent and its affiliates and underscores the company’s strategy of maintaining flexible, market-based access to equity capital while signaling potential dilution and execution risk for existing shareholders, given that actual sales volumes, prices and timing remain uncertain. The most recent analyst rating on (FBLG) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page. **Spark’s Take on FBLG Stock** According to Spark, TipRanks’ AI Analyst, FBLG is a Neutral. The score is held down primarily by weak financial performance (no revenue, widening losses, heavy cash burn) and a strongly bearish technical setup (deeply below key moving averages with negative MACD). Corporate events provide some offset via regained Nasdaq compliance and cost-saving actions, but monitoring/delisting risk and capital structure actions remain notable. Valuation is constrained by a negative P/E and no dividend support. To see Spark’s full report on FBLG stock, click here. **More about FibroBiologics, Inc.** FibroBiologics, Inc. is a publicly listed company that issues common stock on the Nasdaq Capital Market to support its working capital and general corporate purposes. The company accesses U.S. capital markets under an effective shelf registration on Form S-3 to raise funds opportunistically over time through registered offerings. **Average Trading Volume:** 344,378 **Technical Sentiment Signal:** Sell **Current Market Cap:** $4.64M Learn more about FBLG stock on TipRanks’ Stock Analysis page. ### Related Stocks - [FBLG.US](https://longbridge.com/en/quote/FBLG.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)